Key result
Tetrodotoxin had a more powerful inhibitory effect on Ehrlich ascites carcinoma growth than doxorubicin, significantly decreasing mean tumor weight and increasing cumulative mean survival time.
Why the study?
Does tetrodotoxin and/or doxorubicin reduce tumor growth and improve survival in Ehrlich ascites carcinoma-bearing female mice?
Does tetrodotoxin and/or doxorubicin reduce tumor growth and improve survival in Ehrlich ascites carcinoma-bearing female mice?
Tetrodotoxin demonstrates significant antitumor effects and improves survival in a mouse model of Ehrlich ascites carcinoma, potentially outperforming doxorubicin.
Outperforms doxorubicin in this mouse model; leaves open any clinical translation in oncology.
The study aimed to investigate the antitumor effect of tetrodotoxin (TTX) and/or doxorubicin (DOX) on Ehrlich ascites carcinoma (EAC)-bearing mice through the investigated biochemical parameters. TTX and/or DOX with or without N-acetylcystiene were administrated after 10 days into EAC-female mice for a period of 2 weeks in six equal doses. Treatment with TTX or DOX caused a significant decrease in the mean tumor weight and an increase in the cumulative mean survival time when compared with EAC group. All the treatments reduced the elevated liver tumor markers and increased liver antioxidant enzymes under investigation in comparison with EAC. Hepatic cells, suffered severely from degeneration and karriolysis in EAC group, revealed some improvement as appearance of healthy hepatocytes by TTX treatment. The present results suggested that TTX had a more powerful inhibitor effect on EAC growth than DOX and TTX plus DOX treatments reflected by antitumor biochemical and histological studies.
No takes yet. Share an insight, caveat, or question.
ELDAYEM et al. (2012) studied Ehrlich ascites carcinoma. Tetrodotoxin (TTX) and/or doxorubicin (DOX) vs. Untreated EAC group was evaluated on Mean tumor weight and cumulative mean survival time. Tetrodotoxin had a more powerful inhibitory effect on Ehrlich ascites carcinoma growth than doxorubicin, significantly decreasing mean tumor weight and increasing cumulative mean survival time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: